Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Standard BioTools (LAB)
NASDAQ:LAB
Holding LAB?
Track your performance easily
Earnings Data
Report Date
Feb 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.06Last Year’s EPS
-$0.25Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2024
|% Change Since: 6.38%
|Next Earnings Date:Feb 12, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects mixed performance with notable operational efficiencies and cash position strengths, but offset by significant revenue declines and challenges in key segments and markets.Company Guidance
During Standard BioTools' Q3 2024 earnings call, the company reiterated its full-year revenue guidance of $170 million to $175 million, citing $45 million in third-quarter revenue, which marked a 21% sequential increase but a 5% year-over-year decline. The company highlighted the achievement of $80 million in expected synergies from its integration with SomaLogic, contributing to a 24% year-over-year reduction in non-GAAP operating expenses and a 50% improvement in adjusted EBITDA. The revenue mix for the third quarter was comprised of 41% from Lab Services, 31% from Consumables, 14% from Instrument Field Services, and 12% from Instruments. Despite challenges, especially in China, the company is optimistic about growth prospects in consumables and new service offerings, such as Omics as a Service and individual SOMAmer reagents. The firm ended the quarter with $368 million in cash and investments, positioning it to capitalize on strategic opportunities in the life sciences sector.Sequential Revenue Growth
The company reported $45 million in revenue for Q3, representing a 21% sequential increase from the previous quarter.
Operational Efficiency Improvements
The company achieved a 24% year-over-year reduction in non-GAAP operating expenses and a 50% improvement in adjusted EBITDA for the quarter.
Consumables Revenue Growth
Consumables revenue increased by 13% year-over-year in the third quarter, and 21% year-to-date.
Strong Cash Position
The company holds $368 million in cash and short-term investments, indicating a strong capital position.
Launch of Single SOMAmer Reagents
The company launched single SOMAmer reagents as a minimal viable product, making 11,000 individual SOMAmers available for purchase.
---
LAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $1.88 | $1.96 | +4.26% |
| Jul 31, 2024 | $2.24 | $1.42 | -36.61% |
| May 08, 2024 | $2.24 | $2.41 | +7.59% |
| Feb 28, 2024 | $2.37 | $2.25 | -5.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Standard BioTools (LAB) report earnings?
Standard BioTools (LAB) is schdueled to report earning on Feb 12, 2025, TBA Not Confirmed.
What is Standard BioTools (LAB) earnings time?
Standard BioTools (LAB) earnings time is at Feb 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LAB EPS forecast?
LAB EPS forecast for the fiscal quarter 2024 (Q4) is -$0.06.
---